Pharmacology News and Research

Latest Pharmacology News and Research

Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

Pharmaceutical Strategic Initiatives announced today that some of the leading experts in the field of thrombosis and anticoagulation provided their perspective and assessment of new clinical challenges at a recent symposium held at the XXXIII World Congress of the International Society of Hematology held in Jerusalem, Israel on October 12, 2010.

30 Oct 2010

AACR announces launch of new journal, Cancer Discovery

The American Association for Cancer Research announces the launch of its newest journal, Cancer Discovery, which will publish high-impact, peer-reviewed articles describing major advances in basic and clinical research. Its unique format will feature game-changing research, review articles, perspectives and commentaries, news, and "Research Watch" summaries of important journal articles. Cancer Discovery is a new addition to the AACR's robust publication program.

30 Oct 2010

First woman dean of Duke University awarded 2010 Vanderbilt Prize in Biomedical Science

Nancy Andrews, M.D., Ph.D., a groundbreaking researcher and the first woman dean of Duke University School of Medicine, has been awarded the 2010 Vanderbilt Prize in Biomedical Science.

30 Oct 2010

Elevated amounts of SP2 protein turn stem cells into cancerous tumors: Research

Researchers at North Carolina State University have found that the overproduction of a key protein in stem cells causes those stem cells to form cancerous tumors. Their work may lead to new treatments for a variety of cancers.

28 Oct 2010

Viropharma 2010 third quarter net sales increases 46% to $317.4 million

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2010.

27 Oct 2010

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained an initial draft report of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON (OX1).

27 Oct 2010

PAREXEL's white paper provides data on biopharmaceutical, medical device product development

PAREXEL Consulting, a business unit of PAREXEL International and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released a new white paper entitled Drug Innovation, Approval, Market Access, and the New Normal Emerging FDA Review Outcome Trends for New Drugs.

From Parexel 26 Oct 2010

Innovative program for new graduate doctors to ensure safety prescription

A new software based program has recently been created for new graduate doctors to ensure they prescribe safely from day one on the wards.

26 Oct 2010

Researchers investigate impact of fungal toxin on birth defects

A Creighton University School of Medicine researcher has been awarded a $2.7 million grant by the National Institutes of Health (NIH) to investigate a possible link between the ingestion of tortillas and corn-based food products contaminated with a fungal toxin and increased risk for birth defects.

26 Oct 2010

Lead exposure may reverse blindness: Research

Some unexpected effects of lead exposure that may one day help prevent and reverse blindness have been uncovered by a University of Houston (UH) professor and his team.

26 Oct 2010

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Alkermes, Inc. today announced positive topline results from a phase 1 clinical study of an investigational combination of ALKS 33, one of Alkermes' proprietary candidates, and buprenorphine, an existing medication for the treatment of opioid addiction, for the treatment of cocaine addiction.

25 Oct 2010

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

ViroPharma Incorporated today announced that it has completed enrollment in its Phase 2 study evaluating subcutaneous delivery of Cinryze™ (C1esterase inhibitor [human]). This multi-center, open-label, multi-dose Phase 2 study is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze in adolescent and adult subjects with hereditary angioedema (HAE).

25 Oct 2010

Researchers create new high-content assay to increase human embryonic stem cell survival

A new technique for increasing the survival rates of human embryonic stem cells will revolutionize their use in drug discovery and therapy. Human embryonic stem cells often die during the process of isolation using enzymatic disaggregation or low-density plating, which limits their usefulness in drug discovery and basic research. Similarly, the low rate of attachment of implanted cells hinders cell therapy.

25 Oct 2010

BAFF protein can promote aggressive leukemia and lymphomas

Chronic lymphocytic leukemia (CLL) cells survive and thrive not just by their own innate wiles, but by also acquiring aid and support from host cells in their surrounding environment.

25 Oct 2010

Targeting c-Met protein may be effective for patients with metastatic liver cancer

A more personalized treatment for people with a type of metastatic liver cancer hepatocellular carcinoma may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers.

25 Oct 2010

Scientists find two proteins that regulates water retention in salt-sensitive hypertension

Research conducted by scientists at LSU Health Sciences Center New Orleans has found that two proteins in the brain act as valves to turn the hormone that regulates water retention in the body on and off. Their findings may lead to advances in treatment for diseases like high blood pressure, congestive heart failure, and cirrhosis of the liver. The research is published in the November 1, 2010 issue of Endocrinology.

25 Oct 2010

Altogen Biosystems releases PEG-Liposome siRNA In Vivo Transfection Kit

Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins.

22 Oct 2010

Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal

Talecris Biotherapeutics today announced the publication of results from a study showing that PROLASTIN-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 protein in patients with alpha1-antitrypsin (AAT) deficiency.

22 Oct 2010

New review outlines Bionovo's platform of estrogen receptor modulators for menopausal conditions

Bionovo, Inc. today announced the publication of a review of results from studies discussing new classes of estrogen receptor modulating drugs with distinct mechanism for pharmacological effect. The review is published in the most recent edition of Current Opinion in Pharmacology.

22 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

Pharmacology News and Research

Latest Pharmacology News and Research

Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

AACR announces launch of new journal, Cancer Discovery

First woman dean of Duke University awarded 2010 Vanderbilt Prize in Biomedical Science

Elevated amounts of SP2 protein turn stem cells into cancerous tumors: Research

Viropharma 2010 third quarter net sales increases 46% to $317.4 million

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

PAREXEL's white paper provides data on biopharmaceutical, medical device product development

Innovative program for new graduate doctors to ensure safety prescription

Researchers investigate impact of fungal toxin on birth defects

Lead exposure may reverse blindness: Research

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

Researchers create new high-content assay to increase human embryonic stem cell survival

BAFF protein can promote aggressive leukemia and lymphomas

Targeting c-Met protein may be effective for patients with metastatic liver cancer

Scientists find two proteins that regulates water retention in salt-sensitive hypertension

Altogen Biosystems releases PEG-Liposome siRNA In Vivo Transfection Kit

Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal

New review outlines Bionovo's platform of estrogen receptor modulators for menopausal conditions

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

Pittcon Highlights: Pharmaceutical & Biologic eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Pharmacology News and Research

Latest Pharmacology News and Research

Pittcon Highlights: Pharmaceutical & Biologic eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in